Copyright
©The Author(s) 2023.
World J Gastrointest Pathophysiol. Mar 22, 2023; 14(2): 21-33
Published online Mar 22, 2023. doi: 10.4291/wjgp.v14.i2.21
Published online Mar 22, 2023. doi: 10.4291/wjgp.v14.i2.21
Table 1 Number of subjects with non-missing and with missing values for serum anti-Opisthorchis viverrini, alcohol consumption, and smoking dependent on each matched-pair analysis
Principle independent variable | Number of matched pairs | Anti-OV | Alcohol consumption | Smoking | |||
Missing | Non-missing | Missing | Non-missing | Missing | Non-missing | ||
Anti-OV | 95 | Not applicable | 3 | 187 | 2 | 188 | |
GSTM1 | 95 | 10 | 180 | 2 | 188 | 2 | 188 |
GSTT1 | 95 | 10 | 180 | 2 | 188 | 2 | 188 |
CYP2E1 | 93 | 9 | 177 | 2 | 184 | 2 | 184 |
IL6, -634 G/C | 91 | 10 | 172 | 2 | 180 | 2 | 180 |
IL6, -175 G/C | 92 | 10 | 174 | 2 | 182 | 2 | 182 |
IL10, -819 T/C | 91 | 10 | 172 | 2 | 180 | 2 | 180 |
NF-kB, -94 ins/del ATTG | 92 | 10 | 174 | 2 | 182 | 2 | 182 |
Table 2 Relationship between serum anti-Opisthorchis viverrini and cholangiocarcinoma risk, Ubon Ratchathani, Thailand
Number of case-control pairs according to serum anti-OV status: positive (+) vs negative (-) | Crude OR | 95%CI | P value | Adjusted1 OR | 95%CI | P value | Adjusted2 OR | 95%CI | P value | ||||||
Case (+) / Control (+) | Case (+) / Control (-) | Case (-) / Control (+) | Case (-) / Control (-) | LL | UL | LL | UL | LL | UL | ||||||
67 | 23 | 2 | 3 | 11.50 | 2.71 | 48.78 | < 0.001 | 8.96 | 2.06 | 38.99 | 0.001 | 9.40 | 2.16 | 40.85 | 0.003 |
Table 3 Relationship between serum anti-Opisthorchis viverrini, alcohol consumption, and smoking and cholangiocarcinoma risk, Ubon Ratchathani, Thailand, shown by analysis for each of the genetic polymorphisms
Independent variable | Gene adjusted for | Adjusted1 OR | 95%CI | P value | Adjusted2 OR | 95%CI | P value | ||
LL | UL | LL | UL | ||||||
Positive serum anti-OV | GSTM1 | 9.16 | 2.00 | 41.90 | 0.004 | 7.12 | 1.76 | 28.81 | 0.006 |
GSTT1 | 8.16 | 1.85 | 35.96 | 0.006 | 7.33 | 1.74 | 30.93 | 0.007 | |
CYP2E1 | 7.75 | 1.73 | 34.69 | 0.007 | 4.90 | 1.41 | 17.05 | 0.013 | |
IL-6, -174 G/C | 8.07 | 1.80 | 36.07 | 0.006 | 5.39 | 1.51 | 19.29 | 0.010 | |
IL-6, -634 G/C | 7.21 | 1.57 | 32.98 | 0.011 | 6.13 | 1.54 | 24.32 | 0.010 | |
IL-10, -819 T/C | 9.04 | 1.97 | 41.39 | 0.005 | 6.03 | 1.65 | 22.04 | 0.007 | |
NF-kB | 11.81 | 2.31 | 60.44 | 0.003 | 8.14 | 1.90 | 34.90 | 0.005 | |
Alcohol drinking | GSTM1 | 1.06 | 0.70 | 1.60 | 0.779 | 1.12 | 0.76 | 1.67 | 0.560 |
GSTT1 | 1.05 | 0.70 | 1.58 | 0.817 | 1.10 | 0.74 | 1.63 | 0.643 | |
CYP2E1 | 1.05 | 0.70 | 1.58 | 0.801 | 1.10 | 0.75 | 1.63 | 0.614 | |
IL-6, -174 G/C | 1.03 | 0.68 | 1.56 | 0.907 | 1.09 | 0.73 | 1.62 | 0.674 | |
IL-6, -634 G/C | 1.00 | 0.65 | 1.52 | 0.989 | 1.06 | 0.70 | 1.59 | 0.784 | |
IL-10, -819 T/C | 0.98 | 0.63 | 1.53 | 0.933 | 1.06 | 0.70 | 1.61 | 0.785 | |
NF-kB | 0.99 | 0.63 | 1.54 | 0.956 | 1.05 | 0.68 | 1.60 | 0.836 | |
Smoking | GSTM1 | 1.56 | 1.01 | 2.40 | 0.044 | 1.49 | 0.99 | 2.23 | 0.053 |
GSTT1 | 1.56 | 1.01 | 2.42 | 0.044 | 1.51 | 1.00 | 2.27 | 0.049 | |
CYP2E1 | 1.55 | 1.00 | 2.41 | 0.052 | 1.46 | 0.98 | 2.18 | 0.060 | |
IL-6, -174 G/C | 1.73 | 1.05 | 2.85 | 0.030 | 1.62 | 1.04 | 2.54 | 0.035 | |
IL-6, -634 G/C | 1.79 | 1.10 | 2.91 | 0.018 | 1.73 | 1.08 | 2.76 | 0.022 | |
IL-10, -819 T/C | 1.80 | 1.09 | 2.98 | 0.022 | 1.65 | 1.05 | 2.59 | 0.030 | |
NF-kB | 1.78 | 1.08 | 2.94 | 0.023 | 1.80 | 1.11 | 2.91 | 0.016 |
Table 4 Relationship between polymorphisms of drug-metabolizing and inflammation-related enzyme genes and cholangiocarcinoma risk, Ubon Ratchathani, Thailand
Gene | Number of pairs according to gene polymorphism of case and control | Polymorphism | Crude OR | 95%CI | P value | Adjusted1 OR | 95%CI | P value | Adjusted2 OR | 95%CI | P value | |||||||
LL | UL | LL | UL | LL | UL | |||||||||||||
GSTM1 | ||||||||||||||||||
Case | ||||||||||||||||||
Wild | Null | |||||||||||||||||
Control | Wild | 8 | 18 | Wild | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | ||||||||
Null | 18 | 51 | Null | 1.00 | 0.52 | 1.92 | 1.000 | 0.67 | 0.29 | 1.56 | 0.357 | 0.81 | 0.37 | 1.75 | 0.594 | |||
GSTT1 | ||||||||||||||||||
Case | ||||||||||||||||||
Wild | Null | |||||||||||||||||
Control | Wild | 44 | 23 | Wild | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | ||||||||
Null | 21 | 7 | Null | 1.10 | 0.61 | 1.98 | 0.763 | 0.94 | 0.44 | 1.98 | 0.865 | 1.02 | 0.52 | 2.02 | 0.957 | |||
CYP2E1 | ||||||||||||||||||
Case | ||||||||||||||||||
c1/c1 | c1/c2 | c2/c2 | ||||||||||||||||
Control | c1/c1 | 56 | 14 | 4 | c1/c1 | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | |||||||
c1/c2 | 12 | 4 | 2 | c1/c2 | 1.11 | 0.52 | 2.38 | 0.782 | 1.02 | 0.39 | 2.70 | 0.966 | 1.14 | 0.47 | 2.77 | 0.773 | ||
c2/c2 | 1 | 0 | 0 | c2/c2 | 6.19 | 0.74 | 52.08 | 0.093 | 2.02 | 0.20 | 20.67 | 0.552 | 4.17 | 0.45 | 38.24 | 0.207 | ||
c1/c2 or c2/c2 | 1.38 | 0.68 | 2.83 | 0.371 | 1.14 | 0.47 | 2.77 | 0.767 | 1.35 | 0.58 | 3.11 | 0.484 | ||||||
IL-6 | ||||||||||||||||||
Case | -174 | |||||||||||||||||
G/G | G/C | C/C | ||||||||||||||||
Control | G/G | 90 | 0 | 0 | G/G | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | |||||||
G/C | 1 | 0 | 0 | G/C | 0.00 | - | - | - | 0.003 | 0.00 | - | 0.995 | 0.0037 | 0.00 | - | 0.999 | ||
C/C | 0 | 0 | 0 | C/C | - | - | - | - | - | - | - | - | - | - | - | - | ||
IL-6 | -634 | |||||||||||||||||
Case | ||||||||||||||||||
G/G | G/C | C/C | ||||||||||||||||
Control | G/G | 0 | 4 | 5 | G/G | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | |||||||
G/C | 2 | 13 | 12 | G/C | 1.93 | 0.63 | 5.93 | 0.252 | 1.90 | 0.49 | 7.30 | 0.351 | 1.69 | 0.46 | 6.25 | 0.432 | ||
C/C | 4 | 18 | 34 | C/C | 1.28 | 0.44 | 3.73 | 0.654 | 1.38 | 0.40 | 4.71 | 0.607 | 1.45 | 0.43 | 4.87 | 0.551 | ||
G/C or C/C | 1.50 | 0.53 | 4.21 | 0.442 | 1.53 | 0.46 | 5.05 | 0.488 | 1.52 | 0.46 | 4.98 | 0.489 | ||||||
IL-10 | -819 T/C | |||||||||||||||||
Case | ||||||||||||||||||
T/T | T/C | C/C | ||||||||||||||||
Control | T/T | 23 | 15 | 6 | T/T | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | |||||||
T/C | 15 | 17 | 4 | T/C | 0.81 | 0.41 | 1.60 | 0.537 | 0.66 | 0.27 | 1.63 | 0.371 | 0.75 | 0.34 | 1.70 | 0.497 | ||
C/C | 8 | 0 | 3 | C/C | 1.19 | 0.46 | 3.06 | 0.715 | 1.59 | 0.43 | 5.93 | 0.487 | 1.63 | 0.51 | 5.17 | 0.405 | ||
T/C or C/C | 0.91 | 0.51 | 1.65 | 0.763 | 0.85 | 0.39 | 1.87 | 0.686 | 0.95 | 0.47 | 1.93 | 0.891 | ||||||
NF-kB | -94 ins/del ATTG | |||||||||||||||||
Case | ||||||||||||||||||
del/del | ins/del | ins/ins | ||||||||||||||||
Control | del/del | 3 | 5 | 3 | del/del | 1.00 | Reference | 1.00 | Reference | 1.00 | Reference | |||||||
ins/del | 4 | 16 | 13 | ins/del | 0.83 | 0.32 | 2.17 | 0.711 | 1.11 | 0.27 | 4.61 | 0.884 | 0.79 | 0.24 | 2.67 | 0.708 | ||
ins/ins | 9 | 20 | 19 | ins/ins | 0.48 | 0.19 | 1.23 | 0.128 | 0.32 | 0.08 | 1.20 | 0.090 | 0.33 | 0.10 | 1.03 | 0.057 | ||
ins/del or ins/ins | 0.91 | 0.51 | 1.65 | 0.763 | 0.49 | 0.14 | 1.69 | 0.258 | 0.47 | 0.16 | 1.38 | 0.167 |
Table 5 Risk of cholangiocarcinoma due to the combination of polymorphisms of GSTT1 and CYP2E1: Matched case-control study, Ubon Ratchathani, Thailand
- Citation: You G, Zeng L, Tanaka H, Ohta E, Fujii T, Ohshima K, Tanaka M, Hamajima N, Viwatthanasittiphong C, Muangphot M, Chenvidhya D, Jedpiyawongse A, Sripa B, Miwa M, Honjo S. Polymorphism of genes encoding drug-metabolizing and inflammation-related enzymes for susceptibility to cholangiocarcinoma in Thailand. World J Gastrointest Pathophysiol 2023; 14(2): 21-33
- URL: https://www.wjgnet.com/2150-5330/full/v14/i2/21.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v14.i2.21